Key Highlights

  • PLX reported second-quarter 2026 Revenue of $19.9 million, up from $15.7 million a year earlier and beating the $13 million estimate by 53.64 percent.
  • Net income was $3.8 million, or $0.05 per share, compared with $164,000, or $0 per share, in the second quarter of 2025, an increase of 600 percent against the adjusted EPS estimate.
  • First-half 2026 total revenue reached $53.6 million, more than double the $25.8 million reported in the first half of 2025, aided by a $25 million Chiesi milestone payment recognized in the first quarter.
  • The company reaffirmed full-year 2026 revenue guidance, citing continued global penetration of Elfabrio in the Fabry disease market.

Elfabrio Sales Growth Anchors Quarterly Results

Protalix BioTherapeutics, Inc. (NYSE American:PLX), a commercial-stage biopharmaceutical company that develops recombinant therapeutic proteins for rare and orphan diseases using its proprietary plant cell-based protein expression system, said revenue from selling goods rose to $19.8 million from $15.4 million a year earlier, driven mainly by higher Elfabrio sales to partner Chiesi, partially offset by lower sales to Pfizer. Management said the increase in cost of revenues to $7.8 million from $5.9 million reflected the same higher sales volumes to Chiesi.

Because Elfabrio purchase volumes from Chiesi can vary meaningfully from quarter to quarter based on the partner's own inventory management and Manufacturing planning rather than underlying end-market demand, management reiterated that it views the Business on a full-year basis rather than reading too much into any single quarter's shipment pattern.

Fabry Market Expansion Supported by New Dosing Approval

Management pointed to recent European approval of a once-every-four-weeks Elfabrio dosing regimen, along with the product's Patent term extension and a new approval in South Korea, as factors strengthening its Partnership with Chiesi. With the global Fabry disease market projected to reach approximately $3.2 billion by 2031, the company said it believes Elfabrio is positioned to capture 15 to 20 percent of that market over time.

Because this Market Share target depends on continued regulatory approvals and commercial execution by Chiesi across multiple geographies, the pace at which Elfabrio's global penetration expands will remain a key variable investors are likely to track relative to the company's full-year guidance.

PRX-115 Gout Program Advances Toward Late-Stage Data

Research and development expense declined to $4.4 million from $6 million a year earlier, aided by a $2.1 million grant recorded under a new Research and Development law that management said will remain available on an ongoing basis. The company's PRX-115 program, a long-acting differentiated uricase being studied for uncontrolled gout, continued enrollment in its Phase 2 RELEASE study, with site activation nearly complete and enrollment expected to finish within the next five months, keeping the program on track for top-line data in the second half of 2027.

Management noted that competitor Amgen raised prices on its own uricase therapy by more than 20 percent even as volumes declined, a dynamic it characterized as encouraging for the broader gout treatment market given that Amgen's related product revenue is trending from $1.3 billion in 2025 toward an estimated $1.6 billion. Because PRX-115 remains in mid-stage clinical development, however, any read-through to Protalix's own commercial potential remains speculative until its own trial data are available.

Conclusion

Protalix's reaffirmed full-year guidance reflects confidence that continued Elfabrio expansion through its Chiesi partnership, combined with a debt-free Balance Sheet holding $40.7 million in cash and short-term deposits, can sustain the company's current growth trajectory while funding its clinical pipeline. The ongoing Phase 2 RELEASE study in gout represents the next major catalyst, with the ultimate dosing regimen and its associated data expected to shape the design of any subsequent Phase 3 program.